Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.45 |
| ▸ | EGFR | P00533 | 3/20 | 0.45 |
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | IGF1R | P08069 | 4/20 | 0.43 |
| ▸ | PLK4 | O00444 | 2/20 | 0.43 |
| ▸ | WEE1 | P30291 | 2/20 | 0.40 |
| ▸ | AURKA | O14965 | 2/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30086615 | 1.00 | JAK2 (0.45) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL25222783 | 0.91 | JAK2 (0.48) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL30086368 | 0.91 | JAK2 (0.48) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL30086594 | 0.90 | JAK2 (0.47) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL25255420 | 0.90 | JAK2 (0.47) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL23906845 | 0.86 | WEE1 (0.49) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL25273400 | 0.86 | WEE1 (0.49) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL30086977 | 0.86 | WEE1 (0.49) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL25268367 | 0.85 | ACVR1 (0.47) | JAK2EGFRJAK3IGF1RPLK4 | |
| SCHEMBL25218727 | 0.85 | ACVR1 (0.47) | JAK2EGFRJAK3IGF1RPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-12-14 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2021203131-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | JAK2 1187/4885EGFR 545/4885JAK3 1474/4885 |
| US-20230399312-A1 | SUBSTITUTED PYRIMIDINES AND METHODS OF USE | ALK, TYMP, ENTPD5 | JAK2 1187/4885EGFR 545/4885JAK3 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.